



Working to improve your health

17 March 2021

AFT licenses Pascomer® for Europe

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) today announces it has signed a new commercialisation and development agreement for its orphan drug Pascomer®, covering the 27 countries within the European Union as well as Switzerland, Norway and the United Kingdom.

The agreement, with Desitin Arzneimittel GmbH, a specialist pharmaceutical company based in Hamburg, Germany, builds on the 2019 North American commercialisation and development agreement for Pascomer with Timber Pharmaceuticals Inc.

Pascomer is being developed to treat facial angiofibromas, a symptom of Tuberous Sclerosis Complex (TSC), a genetic disease, estimated to affect one in 6,000¹ people, or an estimated 50,000 patients across Europe².

Around 66% of those with TSC over the age of two suffer from facial angiofibromas², which can cause adverse effects on appearance and in serious cases, impair breathing and vision². At present there is no standard treatment for the symptom².

AFT Pharmaceutical Managing Director Dr Hartley Atkinson says: "We are delighted to partner with Desitin, which has excellent coverage and expertise in this therapeutic area across Europe."

Dr Atkinson said the agreement further demonstrated AFT's success in driving the commercialisation of its intellectual property around the world, despite the travel restrictions imposed by the COVID-19 pandemic.

"This is the second major agreement this year that has been entirely negotiated and sealed remotely. Our patented medicines, Maxigesic®, Pascomer and our long-lasting hand sanitiser Crystawash® Extend, are being enthusiastically embraced by partners around the world.

"It is a testament to both the efficacy of these products and the commitment of the AFT team to work through the restrictions of the pandemic to deliver these agreements. They are not only driving improved health outcomes globally, but also driving the realisation of the significant latent value we see in our medicine portfolio," Dr Atkinson said.

Released for and on behalf of AFT Pharmaceuticals by Chief Financial Officer Malcolm Tubby.

For more information:**Investors**

Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Media

Richard Inder
The Project
Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical business with a broad range of products, both developed itself and in-licensed from third parties. AFT's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically, AFT's home markets have been Australia, New Zealand and South-East Asia. However, the company is out-licensing its own products to licensees and distributors to sell in an increasing number of countries around the world. The company's intensive Research and Development program forms the basis of its international sales strategy. For more information about the company, visit our website www.aftpharm.com.

About Desitin Arzneimittel GmbH

Desitin is a German pharmaceutical company who focus on the development and sales of medication for illnesses of the central nervous system in the European continent. Desitin specialize in sophisticated products for the treatment of neurological and psychiatric diseases, with an expertise in skin care.

References

¹Au KS, Williams AT, Roach ES, Batchelor L, Sparagana SP, Delgado MR, et al. Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States. *Genet Med*. 2007 Feb;9(2):88–100.

Dabora SL, Jozwiak S, Franz DN, Roberts PS, Nieto A, Chung J, et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. *Am J Hum Genet*. 2001;68(1):64–80.

²Tuberous Sclerosis Alliance: <https://www.tsalliance.org/>